Richard Stone

Richard Stone, a real estate powerhouse, discusses his $100 million sales strategy of door-knocking only working 100 days a year. He shares insights on selecting walkable areas, being an expert, and embracing generosity. His personal journey includes health struggles, faith, and global travels. A fascinating blend of real estate and life lessons.

Assessing environmental damage during wartime, and tracking signaling between fetus and mother First up, freelance journalist Richard Stone returns with news from his latest trip to Ukraine. This week, he shares stories with host Sarah Crespi about environmental damage from the war, particularly the grave consequences of the Kakhovka Dam explosion. Next, producer Kevin McLean talks with researcher Nardhy Gomez-Lopez, a professor in the department of obstetrics and gynecology and pathology and immunology in the Center for Reproductive Health Sciences at Washington University School of Medicine in St. Louis. The two discuss signaling between fetus and mother during childbirth and how understanding this crosstalk may one day help predict premature labor. Finally, in a sponsored segment from the Science/AAAS Custom Publishing Office, Erika Berg, director and senior editor for the Custom Publishing Office, interviews Andrew Pospisilik, chair and professor of epigenetics at the Van Andel Institute, about his research into how epigenetics stabilizes particular gene expression patterns and how those patterns affect our risk for disease. This segment is sponsored by the Van Andel Institute. This week’s episode was produced with help from Podigy. About the Science Podcast Authors: Sarah Crespi; Kevin McLean; Rich Stone Episode page: https://www.science.org/doi/10.1126/science.z5jiifi Learn more about your ad choices. Visit megaphone.fm/adchoices

Experts Richard Stone and David Sallman discuss novel targets, combinations, and treatment strategies in AML. They explore the potential of drugs Eptenoprop and Magrolumab for TP53-mutated AML, and the importance of mature data sets and specific population focus in phase three trials. The use of complete remission rate as a primary endpoint for TP53 mutant patients is questioned, and CD47 inhibition as a potential therapy is explored.